Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 2/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3028554 | 0.92 | PDE4B (0.61) | PDE4BHDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL3038344 | 0.89 | SLC34A1 (0.43) | PDE4BHCRTR1TNKSTNKS2 | |
| SCHEMBL3037371 | 0.89 | PDE4B (0.54) | PDE4BKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL3036245 | 0.88 | PDE4B (0.53) | PDE4BKMT2AMEN1ALDH1A1KDR | |
| SCHEMBL3032717 | 0.87 | PDE4B (0.52) | PDE4BALDH1A1TDP1 | |
| SCHEMBL3029781 | 0.86 | PDE4B (0.50) | PDE4BKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL3029763 | 0.86 | PDE4B (0.49) | PDE4BHDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL3036003 | 0.85 | PDE4B (0.51) | PDE4BALDH1A1 | |
| SCHEMBL6173388 | 0.85 | PDE4B (0.43) | PDE4BHCRTR1 | |
| SCHEMBL4707488 | 0.84 | PDE4B (0.59) | PDE4BKMT2AMEN1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204241-A9 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | LABORATORIOS ALMIRALL, S. A. | 2010-08-12 | — | — | US | claimed |
| US-20090111819-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | LABORATORIOS ALMIRALL, S. A. | 2009-04-30 | — | — | US | claimed |
| US-7491722-B2 | Pyridazin-3(2H)-one derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2009-02-17 | — | — | US | claimed |
| EP-1575926-B1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | ALMIRALL LAB (ES) | 2008-03-05 | — | — | EP | claimed |
| US-20060173008-A1 | New pyridazin-3(2h)-one derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-08-03 | — | — | US | claimed |
| US-20100204241-A9 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | LABORATORIOS ALMIRALL, S. A. | 2010-08-12 | — | — | US | disclosed |
| US-20090111819-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | LABORATORIOS ALMIRALL, S. A. | 2009-04-30 | — | — | US | disclosed |
| US-7491722-B2 | Pyridazin-3(2H)-one derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2009-02-17 | — | — | US | disclosed |
| EP-1575926-B1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | ALMIRALL LAB (ES) | 2008-03-05 | — | — | EP | disclosed |
| US-20060173008-A1 | New pyridazin-3(2h)-one derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-08-03 | — | — | US | disclosed |
| EP-1575926-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058729-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | ALMIRALL PRODESFARMA SA (ES) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111819-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | PDE4A, PDE3A, PDE3B | PDE4B 5/4885GLO1 2453/4885HDAC6 282/4885 |
| US-20060173008-A1 | New pyridazin-3(2h)-one derivatives | PDE3A, PDE4A, PDE3B | PDE4B 4/4885GLO1 2064/4885HDAC6 447/4885 |
| US-20100204241-A9 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | PDE4A, PDE3A, PDE3B | PDE4B 5/4885GLO1 2453/4885HDAC6 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.